Floatz logo

Bydureon

Chronic Kidney Disease

Baylor Research InstitutePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB

View all 50 →

Same molecule, other indications

Bydureon is also rated in:

diastolic heart failureDormant
BB
Indicative ·
64 / 100
View asset →
type 2 diabetes mellitusDormant
B
Indicative ·
62 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →